Showing 1521-1530 of 1676 results for "".
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Boardhttps://modernod.com/news/alzheimers-therapeutics-research-leader-dr-roy-twyman-joins-neurovision-imaging-board/2480013/Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Board of Directors on July 20. NeuroVision is developing and studying an experimental, breakthrough, low-cost, noninvasive,
- Zeiss Names New Chief Financial Officerhttps://modernod.com/news/zeiss-names-news-chief-financial-officer/2480025/Christian Müller, PhD, will become Chief Financial Officer of Carl Zeiss AG, succeeding Thomas Spitzenpfeil who, as previously announced, will leave the company. Dr. Müller has been CFO of the Zeiss subsidiary Carl Zeiss Meditec AG since 2009. He joined the Zeiss Group in 2002 as head of Corporat
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Topcon Receives FDA Clearance for OCT Angiography on the Maestro2 Systemhttps://modernod.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/Topcon Healthcare has received FDA 510(k) clearance for OCT angiography (OCTA) on the company’s Maestro2 robotic OCT color fundus camera system. According to Topcon, the Maestro2 offers 3×3-mm, 4.5×4.5-mm, and 6x6-mm OCTA scans, which provide the flexibility to le
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Jeff Sieve Appointed CEO of Haag-Streit USAhttps://modernod.com/news/jeff-sieve-appointed-ceo-of-haag-streit-usa/2480518/Haag-Streit has announced that Jeff Sieve is the new Chief Executive Officer for Haag-Streit USA. Mr. Sieve begins his new role immediately, succeeding Ernest Cavin, PhD, who recently left the company to pursue new opportunities. Mr. Sieve will report to Haag-Streit Group management, le
- Kelly K. Nichols, OD, MPH, PhDhttps://modernod.com/profiles/kelly-k-nichols-od-mph-phd/OnxNDv/